The aim of this study to develop galactosylated erlotinib liposomes for treatment of lung
cancer. The liposomes were prepared by using solvent evaporation method. Various …

Erlotinib (ELT) as a small molecule with poor solubility, poor bioavailability, and instability in
gastrointestinal environment, has been considered as a therapeutic agent for Non-Small …

The present investigation was envisaged to develop liposomal formulation for efficacious
and targeted delivery of epidermal growth factor receptor (EGFR) inhibitor (erlotinib) against …

The present study was aimed to develop and optimize nanoliposomes of gefitinib for
effective tumor targeting. Central composite design was used to study the effect of …

In this study, a core-shell type polypeptide-based lipid nanocapsule was developed to
enhance anticancer efficacy of erlotinib in non-small cell lung cancers. Mean particle size of …

Abstract Background and objectives Erlotinib HCl is approved for the treatment of metastatic
non-small cell lung cancer. Owing to its poor aqueous solubility and presystemic …

Synergistic effects of multiple drugs with different modes of action are utilized for
combinatorial chemotherapy of intractable cancers. Translation of in vitro synergistic effects …

During the past few years, advances in drag delivery have provided many opportunities in
the treatment of various diseases and cancer. Arsenic trioxide (ATO) and Erlotinib (Erlo) are …

This contribution is focused on the preparation of a liposomal drug delivery system of
erlotinib resisting the nebulization process that could be used for local treatment of non …

The current study was aimed to prepare a molecular complex of erlotinib (ERL) with
phospholipid (PC) for enhancement of solubility and thus bioavailability, therapeutic efficacy …